Table 4.

Summarized rates of treatment for pregnancy in each investigation (%).

	Burch, 2012	Poppe, 2012	Azizi, 2014	Bartalena, 2015	Negro, 2016	Beshyah, 2017	Wang, 2021
Region	North America	Europe	Asia	Europe	Italy	MENA	Mainland China
Respondents	730	210	310	147	947	352	536
Preferred ATD before pregnancy
PTU	54.3%	42.1%	52%	48.9%	-	9%	84.3%
MMI	45.7%	36.2%	40%	42.3%	61%	36%	15.7%
Carbimazole	-			8.8%	-	54%	-
Switch to PTU in T1
Yes	75.6%	86.5%	96%	75.3%	82.2%	92%	89.4%
No	24.4%	13.5%	4%	24.7%	17.8%	8%	10.6%
Switch to MMI (or CBZ) in T2
Yes	45.9%	46.2%	42%	60%	-	66%	58.8%
No	54.1%	53.8%	58%	40%	-	34%	41.2%

ATD, anti-thyroid drug; CBZ, carbimazole; MENA, Middle East and North Africa; MMI, methimazole; PTU, propylthiouracil; T1, the first trimester; T2 the second trimester.